Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016.. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell NVPlUmQ3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYjJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJFMvPj[nLUC1JO69VQ>? MX3TRW5ITVJ?
CAL-51 cell NXrV[pJRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVTLUpZjUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF{NjDuUS=> Mlq2V2FPT0WU
ABC-1 cell MmfHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlHZTY5pcWKrdHnvckBw\iCqdX3hckBCSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y2KG6P M2rBVnNCVkeHUh?=
A2780 cell M1PIbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVTJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVQhdk1? MWTTRW5ITVJ?
ES1 cell MmPLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmLYTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLke0PUBvVQ>? NWT3ZodrW0GQR1XS
HUTU-80 cell NXXaUY9kT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnPTTY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QTFibl2= NVjxTlY3W0GQR1XS
NCI-H292 cell NWPkSHo1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXnNW5A2UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEi2JI5O MoPuV2FPT0WU
NB69 cell M{XYc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkKyJI5O MWTTRW5ITVJ?
ES8 cell Ml;VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwM{Kgcm0> MYPTRW5ITVJ?
BCPAP cell M{KyXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{WzWmlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM1KG6P M3\UdXNCVkeHUh?=
T-24 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUTJcohq[mm2aX;uJI9nKGi3bXHuJHQuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW1JI5O M1njNXNCVkeHUh?=
EW-16 cell NU[zUo1rT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4mxS2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyKG6P NXzXTog5W0GQR1XS
OVCAR-5 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlWxTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OyCwTR?= NGDUeFhUSU6JRWK=
SF126 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXPJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65OUBvVQ>? MlzMV2FPT0WU
KP-4 cell MkjCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NW\BbWpUUW6qaXLpeIlwdiCxZjDoeY1idiCNUD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yPyCwTR?= MWHTRW5ITVJ?
GAMG cell MlHCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVG0dpc2UW6qaXLpeIlwdiCxZjDoeY1idiCJQV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42OSCwTR?= Mof3V2FPT0WU
HOS cell NWDFenBwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUOgcm0> MYjTRW5ITVJ?
CHL-1 cell NIricGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXuxe29KUW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDFibl2= NFLBNZJUSU6JRWK=
AGS cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXr6W2hFUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg3KG6P NY[z[plzW0GQR1XS
MDA-MB-157 cell MnLES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2\KXWlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVE2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUKgcm0> NInVcHBUSU6JRWK=
HSC-3 cell NVPM[|BqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlXpTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? MmDCV2FPT0WU
CAL-72 cell M4LnTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGDJPGhKdmirYnn0bY9vKG:oIHj1cYFvKEODTD23NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= MlOyV2FPT0WU
NBsusSR cell NWj2TJdCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWnJenZRUW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zMzDuUS=> MYjTRW5ITVJ?
ES7 cell M4LPVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml3MTY5pcWKrdHnvckBw\iCqdX3hckBGWzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkW5JI5O M4H5[3NCVkeHUh?=
H-EMC-SS cell NVX3Smd1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43QCCwTR?= M3uyWHNCVkeHUh?=
NCI-H1703 cell NFT4RYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml3JTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3NFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ6IH7N MnXOV2FPT0WU
BHT-101 cell NXrRNWlVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHm0cWhKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd{IH7N M2HjcnNCVkeHUh?=
SK-OV-3 cell M2HncGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2DwR2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzVibl2= MlLvV2FPT0WU
EW-24 cell NHexPHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmeyTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFMhdk1? M4H6XHNCVkeHUh?=
PSN1 cell MmTaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlTPTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz64OEBvVQ>? MXPTRW5ITVJ?
OVCAR-8 cell NFrnN4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGD2[Y1KdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njl7IH7N NVv4d3h{W0GQR1XS
NCI-H1563 cell NU[zTGlJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2DlV2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=> NX:xV5NPW0GQR1XS
SW756 cell NYD0cGwyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHfRNpdKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yOyCwTR?= NG\ae2dUSU6JRWK=
A375 cell NHLRcFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYjLbm03UW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yPCCwTR?= MnnhV2FPT0WU
Ca9-22 cell M2LPOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJGNiQS1{MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlUhdk1? M3z2PHNCVkeHUh?=
SW1990 cell M4jOS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4DmR2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzOUmwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4{OiCwTR?= NG\lWIVUSU6JRWK=
ES4 cell NYfh[VRzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnzRTY5pcWKrdHnvckBw\iCqdX3hckBGWzRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkO5JI5O NG\kR3JUSU6JRWK=
HCE-T cell NWe2XWhjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVTJcohq[mm2aX;uJI9nKGi3bXHuJGhETS2WIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60OUBvVQ>? M3XYdHNCVkeHUh?=
MOLT-16 cell NHnkW3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV;md4l2UW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC53MzDuUS=> M{juS3NCVkeHUh?=
HSC-4 cell M{HjRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4\aN2lvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlghdk1? NV\P[VFjW0GQR1XS
NCI-SNU-1 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH\leIhKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwOE[gcm0> M3vpWHNCVkeHUh?=
EW-11 cell NHPWblBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND65JI5O MV;TRW5ITVJ?
HT-1080 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWfEcWRsUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57OTDuUS=> MmL2V2FPT0WU
MES-SA/Dx5 cells MVXDfZRwfG:6aXPpeJkh[XO|YYm= NVq3bI44S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{whUUN3ME21JI5O M4jIVVI{QTN5OUix
SW1710 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3fqfGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4yPiCwTR?= MW\TRW5ITVJ?
EW-1 cell M2L1Tmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2\Y[WlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuNlQhdk1? MmThV2FPT0WU
BV-173 cell Ml;zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnzKTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6KG6P M125[3NCVkeHUh?=
TE-8 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkSxJI5O M1[wWnNCVkeHUh?=
G-401 cell M3fsPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX74VopJUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDNibl2= M4XHdnNCVkeHUh?=
KOSC-2 cell MonFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWjLU3hNUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjR3IH7N MWXTRW5ITVJ?
HuCCT1 cell NFXEO49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnTOTY5pcWKrdHnvckBw\iCqdX3hckBJfUOFVEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlUzKG6P M1yze3NCVkeHUh?=
FADU cell M2nVcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MorjTY5pcWKrdHnvckBw\iCqdX3hckBHSUSXIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT62OkBvVQ>? M2T6bXNCVkeHUh?=
MHH-ES-1 cell NHrsXVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoH1TY5pcWKrdHnvckBw\iCqdX3hckBOUEhvRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjlibl2= NV7XbXJsW0GQR1XS
ES3 cell MmXRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVnJcohq[mm2aX;uJI9nKGi3bXHuJGVUOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{mgcm0> MnLoV2FPT0WU
OVCAR-4 cell NHHadFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkW4TY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU45PyCwTR?= NE\seo9USU6JRWK=
HD-MY-Z cell M1XHfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mnj5TY5pcWKrdHnvckBw\iCqdX3hckBJTC2PWT3aJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46OSCwTR?= NV3Ve4h7W0GQR1XS
human JAR cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkTqTY5pcWKrdHnvckBw\iCqdX3hckBLSVJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lkm3JI5O MVHTRW5ITVJ?
A427 cell NGfuU4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHTQPY9KdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlA4KG6P M3raW3NCVkeHUh?=
697 cell Mo\CS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlPMTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkGzJI5O M3znZ3NCVkeHUh?=
OVCAR-3 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVvGUYx[UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5{IH7N M4ezOnNCVkeHUh?=
human NB14 cell NVnhUXc2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFnBTnhKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P MYTTRW5ITVJ?
GB-1 cell MoHHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKGi3bXHuJGdDNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkexJI5O MnTjV2FPT0WU
COR-L105 cell MknuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUHJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44PiCwTR?= Ml\zV2FPT0WU
647-V cell NV\6cVBFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NULGS3piUW6qaXLpeIlwdiCxZjDoeY1idiB4NEetWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvQSCwTR?= MYTTRW5ITVJ?
human K5 cell NE[1VlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXvJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PyCwTR?= NF20dmJUSU6JRWK=
DMS-273 cell NXnsSFVHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIi2R3ZKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N NXLCVJo6W0GQR1XS
UM-UC-3 cell NV7nN|ZbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH7BNnlKdmirYnn0bY9vKG:oIHj1cYFvKFWPLWXDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N NYjNZYhOW0GQR1XS
HEL cell NGDqUXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUXJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEigcm0> NYW3OmhXW0GQR1XS
human KU-19-19 cell NEDZSFdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFXNWHdKdmirYnn0bY9vKG:oIHj1cYFvKEuXLUG5MVE6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yOTDuUS=> M{XBUnNCVkeHUh?=
MC-IXC cell NF7rc3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NITWZW5KdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOTdibl2= NGXpeoNUSU6JRWK=
human H4 cell NVfTdXhoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NITGblBKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz6yOUBvVQ>? MnG3V2FPT0WU
NUGC-3 cell M1PieWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFnrOGZKdmirYnn0bY9vKG:oIHj1cYFvKE6XR1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzNibl2= MXjTRW5ITVJ?
CHP-212 cell NGDCcnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjNTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{PCCwTR?= MkDNV2FPT0WU
human SW982 cell Ml3PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml7kTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOFQhdk1? Mnn3V2FPT0WU
C-33-A cell NH\aV21Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJGMuOzNvQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOVghdk1? NHO1enVUSU6JRWK=
PC-3 cell NVXMd4NRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIjUfolKdmirYnn0bY9vKG:oIHj1cYFvKFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlg6KG6P MXfTRW5ITVJ?
COLO-684 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn7vTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2= NYWwTII4W0GQR1XS
SNU-387 cell NEjSdXRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkXQTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvM{i3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU41QSCwTR?= NVrHTnJ2W0GQR1XS
U251 cell M{S0bmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4e0dWlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPFYhdk1? M3LNfXNCVkeHUh?=
A673 cell NV65XpVQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVzV[Xh7UW6qaXLpeIlwdiCxZjDoeY1idiCDNkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPiCwTR?= M{H5[nNCVkeHUh?=
human T47D cell MmKxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4\iNWlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG2Mlc6KG6P MmT2V2FPT0WU
A549 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHzUeJFKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPU43KG6P NFy4fJhUSU6JRWK=
PC-14 cell NU\SVo16T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV\mN4FTUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI1Njd|IH7N NWrGO|RQW0GQR1XS
A704 cell NVrKe5dzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH3BWYVKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yO{41PSCwTR?= Mlf1V2FPT0WU
MCF7 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIHBSYFKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{PiCwTR?= NHH5e29USU6JRWK=
PC3 cells NE\FN5VHfW6ldHnvckBie3OjeR?= NFT4NmpKdmirYnn0bY9vKG:oIGDET|EudWWmaXH0[YQhSUuWIIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhicnXzbYR2\SCrbjDoeY1idiCSQ{OgZ4VtdHNiYomgSWxKW0FuIFnDOVA:OC5zMUOg{txO NF7aO3MzOTN2MU[3OS=>
F-36P cells NIT3Z4hRem:uaX\ldoF1cW:wIHHzd4F6 M2\PV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRj2zOnAh[2WubIOsJGlEPTB;MD6yPEDPxE1? MYeyNVM1OTZ5NR?=
OCI-AML2 cells MXvQdo9tcW[ncnH0bY9vKGG|c3H5 MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE:FST3BUWwzKGOnbHzzMEBKSzVyPUCuN|Uh|ryP NH7BemYzOTN2MU[3OS=>
K562 cells MoLNVJJwdGmoZYLheIlwdiCjc4PhfS=> MkC1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|LDDJR|UxRTF6IN88US=> MVeyNVM1OTZ5NR?=

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Unknown status Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID